Tafamidis meglumine is primarily used in the treatment of transthyretin amyloidosis, a rare condition where abnormal protein deposits cause damage to tissues and organs, particularly the heart and nerves. It works by stabilizing the transthyretin protein, preventing its misfolding and subsequent formation of amyloid fibrils. This helps slow the progression of the disease, improving patient outcomes and quality of life. It is especially effective in treating cardiomyopathy associated with transthyretin amyloidosis, reducing cardiovascular-related hospitalizations and mortality. The medication is administered orally, making it a convenient option for long-term management of the condition.